Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00259870 · ClinicalTrials.gov registry record · Phase 2
SB-773812 Administered In Adults With Schizophrenia
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 338
- Enrollment target
NCT00259870: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00259870 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 338 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (154% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00259870, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 338 participants
- Enrollment target
Study Summary
This is a two part study designed to evaluate the safety and efficacy of SB-773812 in the treatment of acute schizophrenia. Subjects with acute schizophrenia will be randomized in an adaptive design study to receive placebo, SB-773812 60mg or olanzapine 15mg for 12 weeks in Part A. An interim analysis will be conducted to assess the efficacy and safety of the SB-773812 60mg dose compared with placebo. Based on these data, up to two further doses of SB-773812 will be added to the randomization for Part B.
Interventions
- DRUG Olanzapine
- DRUG SB-773812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
What the finished NCT00259870 record still lists
NCT00259870 is an interventional study that assigns participants to a tested intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (154% higher).
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT00259870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00259870 about?
NCT00259870 is a clinical study titled "SB-773812 Administered In Adults With Schizophrenia". This is a two part study designed to evaluate the safety and efficacy of SB-773812 in the treatment of acute schizophrenia. Subjects with acute schizophrenia will be randomized in an adaptive design study to receive placebo, SB-773812 60mg or olanzapine 15mg for 12 weeks in Part A. An interim analys...
What is the current status of trial NCT00259870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2005-09. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00259870?
The interventions under investigation include: Olanzapine (DRUG), SB-773812 (DRUG).
Who is sponsoring clinical trial NCT00259870?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00259870's enrollment target sits among peer trials
338 140th of 2000 higher than 1,860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia